Can I Take Glycine with Mounjaro (Tirzepatide)?
No published drug interaction study has tested glycine and tirzepatide together, and no shared metabolic enzyme pathway connects them, so a classic pharmacokinetic interaction is not expected. The more relevant question is pharmacodynamic overlap: both compounds can lower blood glucose through separate mechanisms, and that overlap is biologically plausible but has not been directly studied in people taking both. This article separates what is established about each substance individually from what is only a reasonable inference about combining them.
Mounjaro (tirzepatide) is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is FDA-approved for type 2 diabetes and separately approved under the brand name Zepbound for chronic weight management; use for weight loss under the Mounjaro label specifically is off-label. Glycine is a small, conditionally essential amino acid sold over the counter as a dietary supplement, most commonly used for sleep support (typically around 3 g at bedtime) or as part of collagen peptide products.
The direct answer
There is no documented pharmacokinetic interaction between glycine and tirzepatide, and no shared clearance pathway (tirzepatide is degraded proteolytically and cleared renally; glycine is metabolized through the mitochondrial glycine cleavage system). Glycine has insulin-secretagogue activity in some human studies, which creates a theoretical additive glucose-lowering effect when combined with tirzepatide, but this combination has not been tested in a controlled trial as of early 2025. For most people on tirzepatide without insulin or a sulfonylurea, that theoretical overlap is unlikely to produce clinically meaningful hypoglycemia, but people on insulin or a sulfonylurea alongside tirzepatide should treat any new glucose-lowering supplement as something worth monitoring, not something to add silently.
What glycine does in the body
Glycine is the smallest and most abundant amino acid in human tissue. The body makes some endogenously, but many researchers consider it conditionally essential because synthesis may not fully cover demand, particularly during periods of high turnover such as rapid weight loss or illness.
Its recognized roles include:
- Structural protein synthesis. Roughly one in three amino acid residues in collagen is glycine, making it a key building block for skin, tendon, and connective tissue.
- Inhibitory neurotransmission. Glycine acts on receptors in the spinal cord and brainstem associated with muscle relaxation, which is the proposed mechanism behind its use as a sleep aid.
- One-carbon and glucose metabolism. Glycine participates in gluconeogenesis and has been studied as an insulin secretagogue in small human trials, though the size and consistency of this effect vary across the literature and individual study results should be verified against the primary paper before being treated as precise figures.
Small trials have looked at glycine for sleep onset at doses around 3 g before bedtime, and separately for markers of glucose handling at doses in the 3 to 5 g per day range over several weeks. These are modest-sized studies, and exact effect sizes reported in secondary summaries should not be treated as settled without checking the original trial.
How tirzepatide lowers glucose, and where the overlap could occur
Tirzepatide lowers glucose through several linked mechanisms: glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon release, delayed gastric emptying, and reduced caloric intake through central appetite effects. Because insulin release through the GIP and GLP-1 receptor pathways is glucose-dependent, tirzepatide monotherapy carries a comparatively low intrinsic risk of hypoglycemia.
Glycine's proposed insulin-secretagogue effect works through a different receptor, a glycine-gated chloride channel on pancreatic beta cells, and is not described in the literature as glucose-dependent in the same strict way GLP-1/GIP signaling is. The two mechanisms do not share a receptor or enzyme, which is why a pharmacokinetic interaction is not expected. What is plausible, but not established, is that the two glucose-lowering effects could stack in a way that has not been quantified in anyone taking both agents together.
Tirzepatide also slows gastric emptying, most noticeably in the days after each weekly dose escalation. This could delay, but is not expected to reduce, absorption of an oral supplement like glycine taken with food. That is a timing consideration, not a safety concern.
Evidence-status interaction assessment
| Claim | Status | Basis | What to verify before relying on it |
|---|---|---|---|
| Glycine and tirzepatide share a metabolic clearance pathway | Not established / considered unlikely | Tirzepatide is cleared by proteolysis and renal excretion; glycine by the mitochondrial glycine cleavage system. No CYP450 involvement for either. | No dedicated interaction study exists; this is a mechanism-based inference, not a trial finding. |
| Glycine has insulin-secretagogue activity in humans | Plausible, supported by small studies | Reported in small human trials of glycine supplementation on glucose/insulin markers. | Confirm effect size and population in the original trial before quoting a specific number; do not treat secondary summaries as precise. |
| Combining glycine with tirzepatide increases hypoglycemia risk on tirzepatide monotherapy | Not established | No published trial has tested this combination directly. | Ask the prescribing clinician; log fasting glucose for a short period after starting glycine rather than assuming safety or risk. |
| Combining glycine with tirzepatide increases hypoglycemia risk when insulin or a sulfonylurea is also used | Plausible and clinically relevant to flag | Standard pharmacology principle: any added glucose-lowering agent increases risk when a hypoglycemia-capable drug is already in the regimen. | Discuss with the prescriber before adding glycine; consider short-term glucose monitoring. |
| Glycine improves sleep quality at bedtime doses | Supported by small trials in non-GLP-1 populations | Human sleep studies have used roughly 3 g before bed. | These studies were not conducted in people on tirzepatide; extrapolation is reasonable but not directly tested. |
| Glycine or collagen peptides help preserve skin or lean mass during tirzepatide-associated weight loss | Not established for this population | Body-composition studies of collagen peptides exist in other weight-loss contexts, but not specifically alongside tirzepatide. | Do not treat this as a proven mitigation strategy; it is a mechanism-based hypothesis based on collagen's amino acid composition. |
What this means for someone on tirzepatide who wants to add glycine
If you are on tirzepatide alone, or tirzepatide plus metformin, a standard 3 g bedtime dose of glycine is a low-risk starting point based on how each substance is metabolized and the glucose-dependent nature of tirzepatide's insulin effect. Watch for unusual dizziness, sweating, or shakiness in the first two weeks, which would prompt a fasting glucose check.
If you are on tirzepatide plus insulin or a sulfonylurea, the additive glucose-lowering possibility is worth raising with your prescriber before starting glycine, and checking morning fasting glucose for the first one to two weeks after starting is a reasonable precaution rather than an overreaction.
If you have stage 3b or worse chronic kidney disease, discuss any new amino acid supplement with your nephrologist or prescriber, since amino acid load and downstream metabolites are more relevant in reduced renal function. Tirzepatide's own label does not require dose adjustment for eGFR down to 15 mL/min/1.73m², but that does not automatically clear a separate supplement for the same patient.
Timing around injections: if nausea is a problem in the days after your weekly tirzepatide dose, taking glycine on an empty stomach 30 to 60 minutes before bed (the format used in sleep studies) avoids stacking it with a meal during the period when gastric emptying is slowest.
What is genuinely unknown
No controlled trial has enrolled patients taking both tirzepatide and supplemental glycine to measure combined glycemic effect, gastrointestinal tolerability, or any outcome specific to that pairing. Everything above about the combination is inference from how each substance behaves separately, not a result from a study of the combination itself. That inference is reasonable given the distinct, non-overlapping mechanisms, but it is not the same as direct evidence, and a reader should not treat percentage figures or precise glucose numbers attached to this combination as anything other than extrapolation.
When to seek care rather than self-monitor
Contact your prescriber or seek urgent care for symptoms of hypoglycemia (shakiness, sweating, confusion, fainting) especially if you are on insulin or a sulfonylurea, for signs of an allergic reaction to any new supplement, or for persistent vomiting or inability to keep fluids down while on tirzepatide, which can itself cause dehydration and electrolyte problems independent of any supplement.
Frequently asked questions
Can I take glycine while on Mounjaro?
Does glycine interact with Mounjaro?
Will glycine cause hypoglycemia on Mounjaro?
What dose of glycine is commonly used, and does that change with Mounjaro?
Can glycine help with Mounjaro-related nausea or sleep disruption?
Should I tell my doctor I am taking glycine with Mounjaro?
References
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. NDA 215866. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
This article is drafted for editorial and qualified medical review and has not yet received that review. It does not provide individualized dosing or diagnosis. Speak with your prescribing clinician or pharmacist before combining any supplement with tirzepatide, particularly if you take insulin, a sulfonylurea, or have significant kidney disease.